ClinicalTrials.gg
CompletedNCT00728988ALPACSUpdated Feb 21, 2021Results posted

Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome

A Phase 4 interventional study of Atorvastatin and Atorvastatin in Acute Coronary Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
499
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing atorvastatin in Acute Coronary Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Acute Coronary Syndrome.

Enrollment
7th of 17
499 · median 300
Started
2008
the only one that year
Phase 4
11 of 17
1 open now
Registered
9th of 17
by date
Lead sponsor
1 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies testing atorvastatin in Acute Coronary Syndrome, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 11 in phase 4, and was the 9th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

1 of the 17 studies testing atorvastatin in Acute Coronary Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing atorvastatin in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

This present study is specifically designed to examine the efficacy and safety of a high pre-treatment dose of atorvastatin in Asian patients with NSTE-ACS in China and the Republic of Korea, by using a treatment paradigm similar to that employed in the ARMYDA-ACS study.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Asia Lipitor Pre-treatment in Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-ST elevated ACS; LDL-C > 80 mg/dl

Exclusion criteria

Exclusion Criteria:

  • ST elevated acute myocardial infarction; previously or currently treated with atorvastatin or other statins
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
499 participants (actual)

Study arms

  • Experimental
    Atorvastatin Group

    Drug: Atorvastatin

  • Other
    Usual Care Group

    Drug: Atorvastatin

Interventions

  • 80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.

  • 40mg daily after PCI for 30 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI)

    Percentage calculated as: (number of participants who experienced MACE \[death, myocardial infarction, target vessel revascularization\] within 30 days post-PCI) divided by (number of participants who experienced PCI) \* 100. Major Adverse Cardiac Events (MACE) that occurred after 33 days post PCI were excluded.

    Time frame: 30 days post PCI

Secondary outcomes

  1. Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI

    Percentage calculated as: (number of participants who experienced MACE within 8 hours post-PCI) divided by (number of participants who experienced PCI) \* 100.

    Time frame: 8 hours post PCI

  2. Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI

    Percentage calculated as: (number of participants who experienced MACE within 24 hours post PCI) divided by (number of participants who experienced PCI) \* 100.

    Time frame: 24 hours post PCI

  3. Percentage of Participants With Elevated Creatine Kinase-MB (CK-MB)

    CK-MB above the upper limit of normal range from baseline (biomarker of myocardial injury); normal range: 0-5.0 nanograms per milliliter (ng/mL).

    Time frame: 8 hours, 24 hours and 30 days post PCI

  4. Percentage of Participants With Elevated Troponin I

    Troponin I above the upper limit of normal range from baseline (biomarker of myocardial injury): normal range: 0-0.5 nanograms per milliliter (ng/mL).

    Time frame: 8 hours, 24 hours and 30 days post PCI

  5. Percentage of Participants With Elevated Myoglobin

    Myoglobin above the upper limit of normal from baseline (biomarker of myocardial injury): normal range: 0-109 nanograms per milliliter (ng/mL).

    Time frame: 8 hours, 24 hours and 30 days post PCI

  6. Percent Change From Baseline in C-Reactive Protein (CRP)

    C-reactive protein percent change from baseline = (post baseline value minus baseline value) divided by baseline value\*100. Includes all CRP samples tested for the study, including samples unaffected and those samples affected by defective high-sensitivity (hs) CRP reagents.

    Time frame: Baseline, 8 hours, 24 hours and 30 days

07

Results

Posted Sep 27, 2011
Limitations and caveats
Defective high-sensitivity C reactive protein reagents showed instability and 20% average positive bias in results, affecting only change from baseline in CRP. Analyses were performed on all samples; results include affected and unaffected samples.

Participant flow

Participant flow — Overall Study
MilestoneAtorvastatinUsual Care
Started247252
Treated245250
Full analysis set163172
Completed154164
Not completed9388
Withdrew: Not treated22
Withdrew: Death11
Withdrew: Adverse event32
Withdrew: Other8577
Withdrew: Withdrawal by subject26

Outcome measures

PrimaryPercentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI)

Percentage calculated as: (number of participants who experienced MACE \[death, myocardial infarction, target vessel revascularization\] within 30 days post-PCI) divided by (number of participants who experienced PCI) \* 100. Major Adverse Cardiac Events (MACE) that occurred after 33 days post PCI were excluded.

Time frame:
30 days post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI)
percentage of participantsAtorvastatinUsual Care
Total MACE14.715.7
Death0.60.6
Myocardial Infarction14.115.1
Target Vessel Revascularization0.00.0
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.9237 · Mean difference (final values): 1.0 · 95% CI -7.3 to 9.395% confidence interval for the true difference in the incidence of MACE between the two treatment groups. Difference of incidence = usual care minus atorvastatin.
  • Atorvastatin vs Usual Care · Fisher Exact · p = 1.0000 · Mean difference (final values): 0.0 · 95% CI -10.7 to 10.7Confidence limits were calculated by the exact unconditional inference. Difference of incidence = usual care minus atorvastatin.
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.9158 · Mean difference (final values): 1.0 · 95% CI -7.2 to 9.2Difference of incidence = usual care minus atorvastatin.
  • Atorvastatin vs Usual Care · Regression, Logistic · p = 0.80 · Odds ratio (or): 0.93 · 95% CI 0.5104 to 1.6846
  • Atorvastatin vs Usual Care · Regression, Logistic · p = 0.90 · Odds ratio (or): 0.96 · 95% CI 0.4887 to 1.8836
  • Atorvastatin vs Usual Care · Log Rank · p = 0.8494Survival analysis: Kaplan-Meier log rank test.
SecondaryPercentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI

Percentage calculated as: (number of participants who experienced MACE within 8 hours post-PCI) divided by (number of participants who experienced PCI) \* 100.

Time frame:
8 hours post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI
percentage of participantsAtorvastatinUsual Care
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 8 Hours Post-PCI6.76.4
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 1.0000 · Mean difference (final values): 0.4 · 95% CI -5.6 to 6.3Difference of incidence = atorvastatin minus usual care.
SecondaryPercentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI

Percentage calculated as: (number of participants who experienced MACE within 24 hours post PCI) divided by (number of participants who experienced PCI) \* 100.

Time frame:
24 hours post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI
percentage of participantsAtorvastatinUsual Care
Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 24 Hours Post-PCI13.515.1
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.7896 · Mean difference (final values): -1.6 · 95% CI -9.7 to 6.5Difference of incidence = atorvastatin minus usual care .
SecondaryPercentage of Participants With Elevated Creatine Kinase-MB (CK-MB)

CK-MB above the upper limit of normal range from baseline (biomarker of myocardial injury); normal range: 0-5.0 nanograms per milliliter (ng/mL).

Time frame:
8 hours, 24 hours and 30 days post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Elevated Creatine Kinase-MB (CK-MB)
percentage of participantsAtorvastatinUsual Care
8 Hours Post-PCI11.313.6
24 Hours Post-PCI15.618.9
30 Days Post-PCI1.30.0
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.631 · Mean difference (final values): -2.4 · 95% CI -10.1 to 5.4
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.518 · Mean difference (final values): -3.3 · 95% CI -12.1 to 5.5
  • Atorvastatin vs Usual Care · Fisher Exact · p = 0.236 · Mean difference (final values): 1.3 · 95% CI -9.6 to 12.0
SecondaryPercentage of Participants With Elevated Troponin I

Troponin I above the upper limit of normal range from baseline (biomarker of myocardial injury): normal range: 0-0.5 nanograms per milliliter (ng/mL).

Time frame:
8 hours, 24 hours and 30 days post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Elevated Troponin I
percentage of participantsAtorvastatinUsual Care
8 hours post-PCI40.435.5
24 hours post-PCI49.744.4
30 days post-PCI1.91.8
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.425 · Mean difference (final values): 4.9 · 95% CI -6.2 to 15.9
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.392 · Mean difference (final values): 5.3 · 95% CI -6.1 to 16.7
  • Atorvastatin vs Usual Care · Fisher Exact · p = 1.000 · Mean difference (final values): 0.1 · 95% CI -10.7 to 10.9
SecondaryPercentage of Participants With Elevated Myoglobin

Myoglobin above the upper limit of normal from baseline (biomarker of myocardial injury): normal range: 0-109 nanograms per milliliter (ng/mL).

Time frame:
8 hours, 24 hours and 30 days post PCI
Reported as:
Number · percentage of participants
Percentage of Participants With Elevated Myoglobin
percentage of participantsAtorvastatinUsual Care
8 hours post-PCI8.210.8
24 hours post-PCI3.14.2
30 days post-PCI1.30.6
Statistical analysis
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.529 · Mean difference (final values): -2.7 · 95% CI -9.6 to 4.3
  • Atorvastatin vs Usual Care · Chi-squared, Corrected · p = 0.827 · Mean difference (final values): -1.1 · 95% CI -5.8 to 3.6
  • Atorvastatin vs Usual Care · Fisher Exact · p = 0.616 · Mean difference (final values): 0.7 · 95% CI -10.3 to 11.5
SecondaryPercent Change From Baseline in C-Reactive Protein (CRP)

C-reactive protein percent change from baseline = (post baseline value minus baseline value) divided by baseline value\*100. Includes all CRP samples tested for the study, including samples unaffected and those samples affected by defective high-sensitivity (hs) CRP reagents.

Time frame:
Baseline, 8 hours, 24 hours and 30 days
Reported as:
Least squares mean · percent change in CRP
Percent Change From Baseline in C-Reactive Protein (CRP)
percent change in CRPAtorvastatinUsual Care
8 hours post-PCI205.25 ± 67.799234.77 ± 66.135
24 hours post-PCI594.07 ± 110.774543.50 ± 107.730
30 days post-PCI9.01 ± 58.27667.23 ± 56.562
Statistical analysis
  • Atorvastatin vs Usual Care · ANOVA · p = 0.7554 · Mean difference (final values): -29.53 · 95% CI -215.87 to 156.81
  • Atorvastatin vs Usual Care · ANOVA · p = 0.7436 · Mean difference (final values): 50.58 · 95% CI -253.42 to 354.58
  • Atorvastatin vs Usual Care · ANOVA · p = 0.4741 · Mean difference (final values): -58.22 · 95% CI -218.12 to 101.68

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin—16/245 (6.5%)65/245 (26.5%)
Usual Care—16/250 (6.4%)45/250 (18%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAtorvastatinUsual Care
Post procedural myocardial infarctionInjury, poisoning and procedural complications4/2457/250
Myocardial infarctionCardiac disorders3/2454/250
Acute myocardial infarctionCardiac disorders1/2450/250
Atrial fibrillationCardiac disorders1/2450/250
PalpitationsCardiac disorders1/2450/250
Visual impairmentEye disorders1/2450/250
GastritisGastrointestinal disorders1/2450/250
Gastritis erosiveGastrointestinal disorders1/2450/250
Chest painGeneral disorders1/2451/250
DeathGeneral disorders1/2450/250
Most frequent other events
Most frequent other events
EventAtorvastatinUsual Care
HeadacheNervous system disorders29/24518/250
Myocardial infarctionCardiac disorders15/24512/250
Back painMusculoskeletal and connective tissue disorders14/2457/250
Chest painGeneral disorders13/24511/250

Baseline characteristics

Age, Customized
Age, Customized(participants)AtorvastatinUsual CareTotal
18 to 44 years23932
45 to 64 years134156290
>= 65 years9087177
Sex: Female, Male
Sex: Female, Male(Participants)AtorvastatinUsual CareTotal
Female8177158
Male166175341
08

Study locations

26 sites
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510100, China
  • Pfizer Investigational Site
    Changsha, Hunan 410008, China
  • Pfizer Investigational Site
    Shen Yang, Liaoning 110016, China
  • Pfizer Investigational Site
    Shenyang, Liaoning 110004, China
  • Pfizer Investigational Site
    Qingdao, Shandong 266000, China
  • Pfizer Investigational Site
    Hangzhou, Zhejiang 310016, China
  • Pfizer Investigational Site
    Beijing, 100029, China
  • Pfizer Investigational Site
    Beijing, 100034, China
  • Pfizer Investigational Site
    Beijing, 100730, China
  • Pfizer Investigational Site
    Shanghai, 200032, China
  • Pfizer Investigational Site
    Shanghai, 200127, China
  • Pfizer Investigational Site
    Shanghai, 200233, China
  • Pfizer Investigational Site
    Seongnam-si, Gyeonggi-do, Korea 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 602-715, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 705-717, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 705-718, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, Korea, Republic of
  • Pfizer Investigational Site
    Daejeon, 301-721,, Korea, Republic of
  • Pfizer Investigational Site
    Gangneung-si, Gangwon-do, 210-711, Korea, Republic of
  • Pfizer Investigational Site
    Gwang Ju, 501-757, Korea, Republic of
  • Pfizer Investigational Site
    Jinju-si, Gyeongsangnam-do, 660-702, Korea, Republic of
  • Pfizer Investigational Site
    Koyang-shi, 410-719, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 130-702, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 152-703, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, Korea, Republic of
  • Pfizer Investigational Site
    Ulsan, 682-714, Korea, Republic of
09

References and documents

Publications

  • Jang Y, Zhu J, Ge J, Kim YJ, Ji C, Lam W. Preloading with atorvastatin before percutaneous coronary intervention in statin-naive Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol. 2014 May;63(5):335-43. doi: 10.1016/j.jjcc.2013.09.012. Epub 2013 Nov 9. PubMed 24216317 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2008
First posted
Aug 6, 2008
Start
Sep 2008
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Sep 27, 2011
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00728988
Responsible party
Sponsor
First posted
Aug 6, 2008
Start date
Sep 2008
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Sep 27, 2011
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion